1 / 20

Features of Canine Conjunctival Melanocytic Tumors

Purposes. A retrospective study of the histologic and biologic features of canine conjunctival melanocytic tumorsCompare to results of prior studies Biologic behavior and histologic characteristics of canine conjunctival melanomas. Collins BK, Collier LL, Miller MA, Linton LL. Prog in vet and com

lexine
Download Presentation

Features of Canine Conjunctival Melanocytic Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Features of Canine Conjunctival Melanocytic Tumors Reilly CM, Dubielzig RR, Newman SJ and Bergman PJ

    2. Purposes A retrospective study of the histologic and biologic features of canine conjunctival melanocytic tumors Compare to results of prior studies Biologic behavior and histologic characteristics of canine conjunctival melanomas. Collins BK, Collier LL, Miller MA, Linton LL. Prog in vet and comparative ophthalmology; 3:135-140, 1993.

    3. Methods Cases of conjunctival melanocytic tumors selected (COPLOW and AMC) Follow-up surveys mailed to submitting ophthalmologists Only cases with follow-up available were included

    4. Methods (cont.) Slides were evaluated for: Pigmentation Intra- and subepithelial packeting Criteria of malignancy Cell type(s) Mitotic index Necrosis Epithelial dysplasia

    5. Methods (cont.) Survey information included: Breed, gender, age at diagnosis Tumor location (bulbar, TEL, palpebral) Surgery type (incisional, excisional, enucleation, exenteration) Recurrence, metastasis and death

    6. Results 63 cases were identified 24 had follow-up available 14 males, 10 females 8 mixed breeds, 3 labs, 2 cockers, 2 Weimaraners, 2 Shar-peis 1 each Schnauzer, German Shepherd, Poodle, Golden Retriever, Boston Terrier, Pekingese, Newfoundland Age at diagnosis 6-14 y (11.5)

    7. Results – Location 14/23 (61%) on TEL 5/23 (22%) on bulbar conjunctiva 4/23 (17%) on palpebral conjunctiva Location not provided for one tumor

    8. Results - Histologic patterns 14/24 (60%) had packeting of neoplastic cells within conj. epithelium 19/24 (83%) had packeting in subepithelial stroma No correlation with recurrence or metastasis Can be helpful in diagnosis of amelanotic tumors

    10. Results – Benign tumors 3/24 (12%) histologically benign (melanocytomas) None had necrosis, mitoses or dysplasia None recurred or metastasized One was multicentric at diagnosis

    13. Results - malignant 17/21 (81%) at least partially pigmented 5/21 (24%) were spindle cell type 7/21 (33%) were “epithelioid” type 9/21 (43%) were a mixture of both

    16. Results - Recurrence 10/21 (48%) tumors recurred 4/12 (33%) TEL tumors 2/10 (20%) w/ marginal excision 2/3 (67%) w/ complete TEL excision 2/4 (50%) bulbar tumors 3/4 (75%) palpebral tumors One tumor (TEL) had multicentric recurrence

    17. Results – Tumor related death Only 2 tumors (10%) metastasized Both from palpebral conjunctiva 1 dog (5%) euthanized for aggressive regrowth Also from palpebral conjunctiva No dogs with TEL or bulbar tumors died from tumor Palpebral tumors more advanced at diagnosis?

    18. Conclusions Similar to prior report EXCEPT: Even male: female ratio Shar-peis also over represented Metastatic risk may be lower (10% v. 17%) Recurrence even with aggressive surgery Stresses the need for assertive follow-up Especially rare diseases

    19. Acknowledgements Co-authors: Dr. Dick Dubielzig, Rebecca Morris, Dr. Shelley Newman, Dr. Phillip Bergman Technical Assistance: Kate Leiber

    20. Questions?

More Related